<DOC>
	<DOCNO>NCT00811473</DOCNO>
	<brief_summary>The purpose study determine quetiapine fumarate extended-release ( quetiapine XR SEROQUELÂ® XR ) 150 300 mg/day take effective safe treat child adolescent age 10 17 bipolar depression , compare placebo ( non-active tablet , like sugar pill , look like quetiapine ) .</brief_summary>
	<brief_title>Pediatric Bipolar Depression</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>Provision inform consent one parent legal guardian write assent patient study procedure perform . The patient must document clinical diagnosis bipolar I bipolar II disorder , include current episode depress . Patients require outpatient status enrollment randomization visit believe likely remain outpatient duration study . Patients must able swallow study medication tablet . The patient must diagnose Tourette 's Disorder , ObsessiveCompulsive Disorder , acute Posttraumatic Stress Disorder , Panic Disorder , Autistic Disorder and/or Asperger 's Disorder . Patient history nonresponse adequate treatment 2 antidepressant current episode . The patient must receive electroconvulsive therapy ( ECT ) within 30 day participate study . Patients doctor judgement pose current suicidal homicidal risk .</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Bipolar Depression</keyword>
	<keyword>Depression</keyword>
	<keyword>Children</keyword>
	<keyword>Adolescents</keyword>
	<keyword>Seroquel</keyword>
	<keyword>Bipolar Depression Children Adolescents</keyword>
</DOC>